Project Details		
Project Code	MRCIIAR25Ex Neutzmann	
Title	Investigating the impact of epigenetic modifiers, a new treatment for	
	cancer, on fungal pathogens	
Research Theme	Infection, Immunity, Antimicrobial Resistance & Repair	
Summary	Fungal pathogens threaten our health and kill over a million patients	
	worldwide. In this project, we will deploy cutting-edge epigenetics	
	research and medical microbiology to better understand how pathogenic	
	fungi respond to anti-cancer drugs. Our goal is to rationalise the impact	
Description	of cancer treatment on fungal pathogens.	
Description	Recently, a new class of anti-cancer drugs, so called epigenetic modifiers,	
	that target the epigenome of human cells have been developed. These	
	drugs have shown great promise in cancer treatment. However, it is	
	unknown how they affect the growth and pathogenicity of pathogens	
	thriving in immunocompromised cancer patients. Epigenetic	
	modifications and the enzymes that set these modifications are largely	
	conserved throughout eukaryotes. As such, the use of epigenetic	
	modifiers will not only affect human cells but also fungi within the	
	microbiome of the patient, including dangerous fungal pathogens.	
	Fungal pathogens can cause allergic, acute and chronic diseases. A.	
	<i>fumigatus</i> is one of the most important fungal pathogens for human	
	health and can cause fatal invasive infections. A lack of effective	
	treatment against this fungus has led to high mortality rates ranging	
	from 30 – 95 % among infected patients. Due to their weakened immune	
	system, cancer patients are particularly exposed to <i>A. fumigatus</i>	
	infections.	
	In this PhD project, we will test the hypothesis that clinically applied	
	epigenetic modifiers manipulate the epigenome and behaviour of fungal	
	pathogens. Our objectives will be: (i) to characterize the general fungal	
	response to epigenetic modifiers (ii) to define the epigenomic signatures	
	of pathogenic fungi, and (iii) to establish how anti-cancer	
	pharmaceuticals affect the human immune cell – pathogen interaction.	
	In detail, we will investigate how epigenetic modifiers affect growth,	
	morphology and stress resistance of <i>A. fumigatus</i> . As such, we will	
	coincubate the fungus with different epigenetic modifiers, which have	
	been selected for target specificity and relevance in clinical settings. In	
	our pilot analyses, we have observed that epigenetic modifiers induce	
	macroscopic changes to fungal morphology and change the fungal	
	response to antifungal drugs. We will further assess how treatment with	
	epigenetic modifiers will affect fungal resistance to host stresses,	
	antifungals, antimicrobial peptides and co-incubation with human	
	immune cells. Then, we will analyse the changes to the fungal	
	transcriptome and epigenome induced by the epigenetic modifiers by	
	RNAseq, Western blot and Cut&Tag. These molecular experiments will	
	enable us to identify the areas of the genome that are affected by the	
	epigenetic modifiers and help us to understand the epigenetic response	

	of the pathogen to anti-cancer pharmaceuticals. In addition, we will perform biochemical analyses to identify and characterise the target proteins of the epigenetic modifiers and their molecular interaction. Together, these analyses will advance our understanding of the effects of drugs applied to cancer patients on fungal pathogens and provide an exemplar case for the central role of epigenetics in fungal pathogenicity. The knowledge gained from this project will help to optimise the treatment regime of immunocompromised patients to prevent the proliferation of fungal pathogens. Overall, this PhD project will offer multidisciplinary training in molecular biology as well as medical mycology - vital skills for establishing a successful career in medical biology. It will be embedded in a collaboration between the MRC Centre for Medical Mycology, the Biosciences Department in Exeter and the Milner Centre for Evolution, Bath, and will provide access to a world-leading network of scientists. Throughout the project, the prospective student will actively participate in the design of the project and is encouraged to bring in their own research ideas.
Supervisory Team	
Lead Supervisor	
Name	Dr Hans-Wilhelm Nuetzmann
Affiliation	Exeter
College/Faculty	HLS
Department/School	Biosciences
Email Address	h.nuetzmann@exeter.ac.uk
Co-Supervisor 1	
Name	Dr Johannes Rack
Affiliation	Exeter
College/Faculty	HLS
Department/School	Biosciences
Co-Supervisor 2	
Name	Dr Neil Brown
Affiliation	Bath
College/Faculty	Science
Department/School	Life Sciences

Biosciences

Exeter HLS

Professor Adilia Warris

Co-Supervisor 3

Affiliation College/Faculty Department/School

Name